The upcoming UN general assembly resolution on tuberculosis must also benefit children

Great progress has been made in recent years towards the development of improved tools for tuberculosis. We now have a 3-month, once-weekly regimen for tuberculosis prevention (isoniazid and rifapentine), rapid molecular tests to diagnose drug-susceptible and drug-resistant tuberculosis, a 9-month regimen that cures 80% of patients with multidrug-resistant (MDR) tuberculosis,1 and two new drugs (bedaquiline and delamanid) that have been approved by stringent regulatory authorities. However, the progress for children, who have only recently been recognised to have a huge burden of tuberculosis disease, has been minimal.